2
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Terminated
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Gastrointestinal
1
Conditions
Colorectal Neoplasms
498
Rectal Neoplasms
268
Colonic Neoplasms
219
Pancreatic Neoplasms
190
Stomach Neoplasms
183
Esophageal Neoplasms
135
Breast Neoplasms
119
Neoplasm Metastasis
117
Squamous Cell Carcinoma of Head and Neck
95
Head and Neck Neoplasms
92
Neoplasms
90
Adenocarcinoma Of Esophagus
67
Esophageal Squamous Cell Carcinoma
62
Carcinoma, Hepatocellular
56
Adenocarcinoma
40
Nasopharyngeal Carcinoma
35
Cholangiocarcinoma
33
Biliary Tract Neoplasms
27
Anus Neoplasms
26
Gastrointestinal Neoplasms
25
Carcinoma, Squamous Cell
25
Carcinoma, Non-Small-Cell Lung
25
Keratosis, Actinic
23
Gallbladder Neoplasms
22
Liver Neoplasms
21
Urinary Bladder Neoplasms
20
Parkinson Disease 4, Autosomal Dominant Lewy Body
20
Bile Duct Neoplasms
19
Ovarian Neoplasms
16
Carcinoma
16
Interventions
Lenalidomide
4
Gemcitabine
4
Dexamethasone
4
Cyclophosphamide
4
Bortezomib
4
Nivolumab
3
Cisplatin
3
Carboplatin
3
vandetanib
2
tumor necrosis factor-alpha, CNGRC fusion protein, human
2
pomalidomide
2
pembrolizumab
2
liposomal doxorubicin
2
fludarabine
2
durvalumab
2
capivasertib
2
Radiosurgery
2
Paclitaxel
2
Doxorubicin
2
Bevacizumab
2
Anthropogenic Effects
2
venetoclax
1
umbralisib
1
ublituximab
1
tremelimumab
1
tivozanib
1
ricolinostat
1
regorafenib
1
pazopanib
1
niraparib
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Disease Progression
×
Fluorouracil
×
Clear all
NCT05712356
2026-05-26
BOLSTER
Lisata Therapeutics, Inc.
Phase 2
Terminated
66 enrolled
12 charts